Novavax Executive and Leadership Team

John Jacobs, the President, Chief Executive Officer & Member of The Board of Directors at Novavax, directs the overarching corporate strategy and long-term vision for the biotechnology firm. Jacobs manages the integration of recombinant protein technology into global markets while overseeing the strategic partnership with Sanofi to maximize vaccine commercialization. By aligning the Board of Directors with operational goals, the President, Chief Executive Officer & Member of The Board of Directors ensures the company maintains a competitive edge in the infectious disease sector. John Jacobs drives the expansion of the vaccine pipeline, focusing on COVID-19, influenza, and respiratory syncytial virus initiatives. This leadership role involves navigating complex regulatory landscapes and securing financial stability through licensing agreements. Ultimately, the President, Chief Executive Officer & Member of The Board of Directors secures the future of the organization by fostering innovation and operational excellence across all international research and development divisions.

Louis Fries, the Chief Medical Officer at Novavax, oversees the medical integrity and safety profiles of all vaccine candidates within the biotechnology pipeline. Fries directs the clinical evaluation of nanoparticle technology and patented adjuvants to ensure robust immune responses against pathogens like malaria and shingles. The Chief Medical Officer collaborates with global health authorities to validate the efficacy of the recombinant protein approach. Louis Fries manages the medical strategy for ongoing clinical trials, ensuring adherence to rigorous scientific standards. By providing medical guidance to the research teams, the Chief Medical Officer facilitates the transition of candidates from laboratory discovery to commercialization. This role involves constant monitoring of clinical data to support regulatory filings and public health initiatives. Ultimately, Fries maintains the highest standards of patient safety and medical excellence, ensuring the company delivers reliable solutions for serious infectious diseases across diverse global populations.

Raburn Mallory, the Senior Vice President, Head of Clinical Development and Deputy Chief Medical Officer at Novavax, executes the operational framework for all clinical trial phases. Mallory directs the design and implementation of study protocols for respiratory syncytial virus and COVID-19 vaccine candidates. The Senior Vice President, Head of Clinical Development and Deputy Chief Medical Officer coordinates with internal research teams to optimize the application of the proprietary adjuvant platform. Raburn Mallory manages the execution of clinical development timelines, ensuring that data collection meets the requirements for international regulatory approval. By overseeing the clinical development lifecycle, the Senior Vice President, Head of Clinical Development and Deputy Chief Medical Officer bridges the gap between scientific discovery and market readiness. This leadership role involves managing complex trial logistics and ensuring data quality across all research sites. Ultimately, Mallory accelerates the delivery of life-saving vaccines by streamlining clinical processes and maintaining rigorous scientific oversight.

Mark Casey, the Executive Vice President & Chief Legal Officer at Novavax, directs the legal strategy and intellectual property protection for the company's proprietary vaccine technology. Casey manages the negotiation of licensing and collaboration agreements with major global pharmaceutical entities to support the commercialization of the vaccine pipeline. The Executive Vice President & Chief Legal Officer oversees corporate governance and ensures compliance with international regulatory requirements across all operational regions. Mark Casey provides legal counsel to the Board of Directors regarding risk management and strategic partnerships. By safeguarding the company's intellectual property, the Executive Vice President & Chief Legal Officer enables the continued exploration of the adjuvant platform in oncology and infectious disease research. This role involves navigating complex legal frameworks to protect the organization's interests while fostering growth. Ultimately, Casey secures the legal foundation necessary for the company to innovate and deliver critical health solutions to the global market.